Annual Accounts Receivable
$270.90 K
-$355.60 K-56.76%
September 30, 2024
Summary
- As of February 24, 2025, EDSA annual accounts receivable is $270.90 thousand, with the most recent change of -$355.60 thousand (-56.76%) on September 30, 2024.
- During the last 3 years, EDSA annual accounts receivable has fallen by -$3.03 million (-91.80%).
- EDSA annual accounts receivable is now -91.80% below its all-time high of $3.30 million, reached on September 30, 2021.
Performance
EDSA Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$350.60 K
+$79.70 K+29.42%
December 31, 2024
Summary
- As of February 24, 2025, EDSA quarterly accounts receivable is $350.60 thousand, with the most recent change of +$79.70 thousand (+29.42%) on December 31, 2024.
- Over the past year, EDSA quarterly accounts receivable has dropped by -$761.70 thousand (-68.48%).
- EDSA quarterly accounts receivable is now -95.51% below its all-time high of $7.81 million, reached on March 31, 2021.
Performance
EDSA Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
EDSA Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -56.8% | -68.5% |
| 3 y3 years | -91.8% | +717.3% |
| 5 y5 years | +24.8% | +717.3% |
EDSA Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -91.8% | at low | -87.8% | +717.3% |
| 5 y | 5-year | -91.8% | +209.9% | -95.5% | +717.3% |
| alltime | all time | -91.8% | >+9999.0% | -95.5% | >+9999.0% |
Edesa Biotech Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $350.60 K(+29.4%) |
| Sep 2024 | $270.90 K(-56.8%) | $270.90 K(-50.8%) |
| Jun 2024 | - | $551.10 K(-50.5%) |
| Mar 2024 | - | $1.11 M(+49.6%) |
| Dec 2023 | - | $743.60 K(+18.7%) |
| Sep 2023 | $626.50 K(-50.1%) | $626.50 K(+1360.4%) |
| Jun 2023 | - | $42.90 K(-14.5%) |
| Mar 2023 | - | $50.20 K(-60.0%) |
| Dec 2022 | - | $125.50 K(-90.0%) |
| Sep 2022 | $1.26 M(-62.0%) | $1.26 M(-10.6%) |
| Jun 2022 | - | $1.40 M(+12.3%) |
| Mar 2022 | - | $1.25 M(-56.6%) |
| Dec 2021 | - | $2.88 M(-12.9%) |
| Sep 2021 | $3.30 M(+3678.9%) | $3.30 M(-21.1%) |
| Jun 2021 | - | $4.19 M(-46.4%) |
| Mar 2021 | - | $7.81 M(+4548.9%) |
| Dec 2020 | - | $168.00 K(+92.2%) |
| Sep 2020 | $87.40 K(-59.7%) | $87.40 K(+54.7%) |
| Jun 2020 | - | $56.50 K(-32.8%) |
| Mar 2020 | - | $84.10 K(-23.3%) |
| Dec 2019 | - | $109.60 K(-68.2%) |
| Sep 2019 | $217.10 K(+426.9%) | - |
| Jun 2019 | - | $345.00 K(+762.5%) |
| Mar 2019 | - | $40.00 K(-44.2%) |
| Dec 2018 | - | $71.70 K(+74.0%) |
| Sep 2018 | $41.20 K(+3069.2%) | $41.20 K(+300.0%) |
| Jun 2018 | - | $10.30 K(-83.6%) |
| Mar 2018 | - | $62.80 K(+470.9%) |
| Dec 2017 | - | $11.00 K(+746.2%) |
| Sep 2017 | $1300.00 | $1300.00(-89.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $11.90 K(-81.9%) |
| Mar 2017 | - | $65.90 K(+410.9%) |
| Dec 2016 | - | $12.90 K(-85.0%) |
| Sep 2016 | $85.80 K(-45.6%) | $85.80 K(+853.3%) |
| Jun 2016 | - | $9000.00(-13.5%) |
| Mar 2016 | - | $10.40 K(-70.8%) |
| Dec 2015 | - | $35.60 K(-77.4%) |
| Sep 2015 | $157.60 K(+256.6%) | $157.60 K(+39.5%) |
| Jun 2015 | - | $113.00 K(+580.7%) |
| Mar 2015 | - | $16.60 K(-53.9%) |
| Dec 2014 | - | $36.00 K(-36.4%) |
| Sep 2014 | $44.20 K(-21.9%) | - |
| Aug 2014 | $56.60 K(+221.6%) | $56.60 K(+1032.0%) |
| May 2014 | - | $5000.00(-90.1%) |
| Feb 2014 | - | $50.60 K(+892.2%) |
| Nov 2013 | - | $5100.00(-71.0%) |
| Aug 2013 | $17.60 K(+252.0%) | $17.60 K(+252.0%) |
| May 2013 | - | $5000.00(0.0%) |
| Feb 2013 | - | $5000.00(-81.5%) |
| Nov 2012 | - | $27.10 K(+442.0%) |
| Aug 2012 | $5000.00(+25.0%) | $5000.00(-89.2%) |
| May 2012 | - | $46.30 K(+46.5%) |
| Feb 2012 | - | $31.60 K(-86.2%) |
| Nov 2011 | - | $228.20 K(+5605.0%) |
| Aug 2011 | $4000.00(-98.2%) | $4000.00(-86.4%) |
| May 2011 | - | $29.40 K(+28.4%) |
| Feb 2011 | - | $22.90 K(-65.7%) |
| Nov 2010 | - | $66.80 K(-69.5%) |
| Aug 2010 | $218.80 K | $218.80 K(+353.9%) |
| May 2010 | - | $48.20 K |
FAQ
- What is Edesa Biotech annual accounts receivable?
- What is the all time high annual accounts receivable for Edesa Biotech?
- What is Edesa Biotech annual accounts receivable year-on-year change?
- What is Edesa Biotech quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Edesa Biotech?
- What is Edesa Biotech quarterly accounts receivable year-on-year change?
What is Edesa Biotech annual accounts receivable?
The current annual accounts receivable of EDSA is $270.90 K
What is the all time high annual accounts receivable for Edesa Biotech?
Edesa Biotech all-time high annual accounts receivable is $3.30 M
What is Edesa Biotech annual accounts receivable year-on-year change?
Over the past year, EDSA annual accounts receivable has changed by -$355.60 K (-56.76%)
What is Edesa Biotech quarterly accounts receivable?
The current quarterly accounts receivable of EDSA is $350.60 K
What is the all time high quarterly accounts receivable for Edesa Biotech?
Edesa Biotech all-time high quarterly accounts receivable is $7.81 M
What is Edesa Biotech quarterly accounts receivable year-on-year change?
Over the past year, EDSA quarterly accounts receivable has changed by -$761.70 K (-68.48%)